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Summary Twenty cases of interstitial pneumonia secondary to treatment with granulocyte colony-stimulating factor (G-CSF) were reviewed.
Their interstitial pneumonia had the following features: (a) it occurred predominantly in patients aged 60 years or older; (b) it was prevalent
among patients with haematological malignancies, particularly non-Hodgkin's lymphoma; (c) in all patients G-CSF was given after anti-cancer
agents with potential to affect the lungs; (d) at the onset, many patients had symptoms such as dyspnoea and fever; and (e) the leucocyte
(neutrophil) count as well as lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels were usually higher than normal at the onset.
These findings indicate that, when G-CSF is used in combination with pneumotoxic anti-cancer agents, respiratory function should be
monitored before and during treatment. If the leucocyte (or neutrophil) count and/or LDH and CRP increase suddenly in association with
dyspnoea and fever during administration of G-CSF, interstitial pneumonia should be suspected. Accordingly, a chest radiograph and
pulmonary functional tests should be performed promptly. If a diagnosis of interstitial pneumonia is made, steroid pulse therapy should be
commenced immediately.
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Granulocyte colony-stimulating factor (G-CSF) is used to treat
granulocytopenia secondary to cancer chemotherapy and bone
marrow transplantation. It is effective in reducing the occurrence
offever and infection associated with granulocytopenia. Although
the well-known adverse events ofG-CSF are fever, bone pain and
liver dysfunction, these problems are largely transient and disap-
pear after the completion of treatment (Niitsu and Umeda, 1994).
Recently, compared with many other countries, interstitial pneu-
monia possibly related to G-CSF administration appears to be
more frequently observed in Japan (lki et al, 1993; Katoh et al,
1993; Okubo and Nakazawa 1993; Murayama et al, 1994),
although the link between pneumonitis and G-CSF has not been
clearly explained. GM-CSF, another haematopoietic growth
factor, has been associated with adult respiratory distress
syndrome (ARDS) and acuterespiratory insufficiency (Wiley et al,
1993). Precise knowledge ofthe characteristics ofinterstitial pneu-
monia due to G-CSF is necessary for early diagnosis and this may
allow us to improve the outcome. Accordingly, we reviewed cases
ofinterstitial pneumonia secondary to G-CSF therapy reported in
Japan to clarify its clinical characteristics as well as possible
methods ofdiagnosis and treatment.
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MATERIALS AND METHODS
The subjects of this study were patients receiving either filgrastim
or lenograstim and who presented symptoms consistent with the
diagnosis for interstitial pneumonia between November 1991 and
January 1996 by the criteria shown below. The criteria for diag-
nosis of interstitial pneumonia were determined as follows: (a)
chest radiograph films and computerized tomography (CT) scans
that showed findings characteristic of interstitial pneumonia; (b)
the PaO2 was < 70 mmHg at onset or decreased by 20 mmHg after
administration ofG-CSF; (c) infection and tumour metastasis were
excluded by bacteriological, cytological and histological examina-
tion of sputum, bronchoalveolar lavage fluid and transbronchial
biopsy specimens that were used to detectbacteria, fungi, protozoa
and viruses or because neither organisms nor tumour cells were
detected in any ofthese specimens; and (d) interstitial pneumonia
developed within 10 days of completion of G-CSF therapy after
administration of anti-cancer agents. Patients with a history of
lung disease were not included in this study. Twenty patients were
diagnosed with interstitial pneumonia using the above criteria
and all of them were reported to the Japanese Ministry of Health
and Welfare.
RESULTS
Background data on patients
The 20 patients with concurrent interstitial pneumonia were aged
63 years on average and 14 were at least 60 years old, indicating
that it predominantly affected elderly patients. The primary
16611662 N Niitsu etal
Table 1 Characteristics of patients who developed interstitial pneumonia
during treatment with recombinant human granulocyte colony-stimulating
factor
Number of patients
Median age (range) years
Sex: male/female
20
63 (41-73)
10/10
Diagnosis
Non-Hodgkin's lymphoma
Histology (working formulation)
Low grade
Follicular
Intermediate grade
Diffuse large
Diffuse mixed
Diffuse small cleaved
High grade
Immunoblastic
Primary/relapse
Phenotype
T/B/unknown
Stage (Ann Arbor)
l/lWl/IV/unknown
Acute monocytic leukaemia (M5b*)
Performance status (WHO)
0/1/2/3/4/unknown
19
10
6
1
18/1
4/10/5
4/5/8/2
1
10/1l12101314
*French-American-British classification.
disease was haematological malignancy in all 20 patients.
Nineteen of them had non-Hodgkin's lymphoma (NHL) and one
had acute monocytic leukaemia (M5b: French-American-British
classification). NHL was of intermediate grade in 89.5% and
mainly in the advanced stages according to the Ann Arborclassifi-
cation (Table 1). On admission, none of the patients showed any
significant changes in peripheral blood findings, pulmonary func-
tion, immunology or coagulation parameters (Table 2).
Association of interstitial pneumonia with
chemotherapy regimens, number of chemotherapy
courses and response to treatment (Table 3)
All 20 patients received G-CSF as adjuvant therapy during cancer
chemotherapy.
Thechemotherapy regimens used always included pneumotoxic
agents, such as cyclophosphamide (CPA), bleomycin (BLM),
methotrexate (MTX) and etoposide (VP-16). Interstitial pneu-
monia developed most commonly (in seven patients) during the
second course of chemotherapy and in 15 patients before the
fourth course of chemotherapy. The median total doses of
pneumotoxic chemotherapy agents were CPA 1800 mg i-2
(584-5250), BLM 18 mg in2 (11-55), MTX 1137 mg i-2
(321-3094), VP-16 394 mg in2 (345-1859) and the numbers of
treated patients were 19 (95%), 11 (55%), 5 (25%), and 4 (20%)
Table 2 Comparisons of laboratory findings between baseline and at onset of interstitial pneumonia during treatment with
recombinant human granulocyte colony-stimulating factor
Baseline At onset of Interstitial pneumonia
Haematological examinations
WBC (rd)
Neutrophil (j.)
Platelet (x 104 jl-1)
RBC (x 104gl-1)
Haemoglobin (g dl-')
LDH (IU I-')
CRP (mg dl-1)
Immunological examinations
IgA (mg dl-')
IgG (mg dl-1)
IgM (mg dl-')
T cell (%)
B cell (%)
CD4 (%)
CD8 (%)
CD4/CD8 ratio
Pulmonary function test
paO2 (kPa)
PaCO2 (kPa)
AadO2 (kPa)
%DLCO
Coagulation test
PT (second)
APTT (second)
FDP (igg ml-')
Fibrinogen (mg dl-')
D-dimer (ng ml-')
5100(1700-11300)
2438 (816-8995)
23.8 (2-46)
429.5 (302-470)
12.4 (8-14)
331 (212-646)a
0.3 (0-3.44)a
291 (191-438)
1841 (1460-5174)
171 (84-722)
92 (82.1-98)
2 (1-8)
28.6 (27.2-48.3)
21.4 (7.6-48.4)
1.41 (0.68-6.36)
11.5 (10.0-13.4)
5.3 (4.6-5.5)
2.0 (0.1-4.4)
93 (82-98)
11.4 (10.0-11.9)
33.4 (26.2-43.6)
<10
384(126-561)
<100
10000(3800-41500)
8000 (2700-20925)
18.5 (0.9-162)
332 (13.4 448)
10.4 (7-13)
607 (248-1072)
3.2 (0-26.2)
186 (129-371)
1620 (591-2090)
124 (50-268)
92 (87-98)
3 (1-8)
30.1 (28.6-34.5)
25.9 (14.9-38.1)
1.32 (0.85-2.01)
7.0 (4.3-9.7)
4.5 (3.6-6-1)
7.4 (3.0-10.4)
11.4 (10.1-11.8)
36.0 (27.4-43)
<10
403 (145-555)
<100
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Values are given as median (range). aDuring chemotherapy before G-CSF administration and before onset of interstitial
pneumonia episode. Abbreviations: WBC, white blood cell; RBC, red blood cell; PaO2, partial pressure of arterial oxygen,
PaCO2, partial pressure of arterial carbon dioxide; AaDO2, arterial-alveolar difference ofoxygen; DLCO, pulmonarydiffusing
capacity for carbon monoxide; PT, prothrombin time; APTT, activated partial thromboplastin time; FDP, fibrinogen degradation
products.
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Table 3 Chemotherapy regimens, clinical response and total dose of anti-cancer agents and G-CSF until onset of interstitial pneumonia in the 20 patients
Anticanceragentsa G-CSFb
Number Sex Age Diagnosis Chemotherapy Course Clinical CPA BLM MTX VP-16 (gg per Durations
regimen at onset response (mg m-2) (mg m-2) (mg m-2) (mg m-2) body) (day)
1 M 41 NHL Pro-MACE 2 CR 2652 3094 442 1650 12
2 M 56 NHL COP-BLAMIII 1 PR 782 28 600 4
3 F 63 NHL COPP/CHOP 2 PR 1242 375 5
4 F 65 NHL COP-BLAMIII 4 CR 1655 29 750 10
5 F 62 NHL COP-BLAMIII 7 CR 1972 55 450 6
6 F 66 NHL COP-BLAM 2 CR 584 15 300 4
7 M 73 AMoL AraC + VP-16 4 PR 1859 1280 8
8 M 71 NHL ProMACE-CytaBOM 4 CR 1728 14 321 346 450 6
9 F 68 NHL CHOP 4 PR 2786 1790 19
10 F 66 NHL CHOP 2 CR 800 570 5
11 F 47 NHL CHOP 4 CR 4000 400 4
12 M 69 NHL CHOP 2 PD 706 700 7
13 F 64 NHL DXR+VP-16+CPA+VCR+BLM+PSL 6 CR 3500 17 345 345 500 5
14 F 55 NHL COP-BLAM 2 CR 1200 15 600 6
15 M 48 NHL COP-BLAM 3 PR 1800 1 1 700 6
16 F 63 NHL COP-BLAM 3 CR 1800 21 600 6
17 M 49 NHL MACOP-B 12 weeks Unknown 2160 30 1240 600 5
18 M 62 NHL MACOP-B 11 weeks Unknown 1989 18 1137 1750 14
19 M 62 NHL CHOP 7 CR 5250 1100 12
20 M 67 NHL CHOP 2 CR 1500 1100 12
aTotal dose administered until onset of interstitial pneumonia episode. bTotal dose administered only course at onset of interstitial pneumonia episode.
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; COPP, cyclophosphamide, vincristine, procarbazine, prednisolone; ProMACE-
CytaBOM, prednisolone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine; COP-BLAM, COP-BLAMIII,
cyclophosphamide, vincristine, prednisolone, bleomycin, doxorubicin, procarbazine; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine,
prednisolone, bleomycin; CR, complete remission; PR, partial remission; PD, progressive disease.
respectively. Out of the 18 patients whose clinical response was
reported and was available, 17 (94%) achieved complete remission
or partial remission. Interstitial pneumonia developed most
frequently (in 12 patients) during the administration ofG-CSF and
in three other patients within 3 days ofcompletion of administra-
tion of G-CSF. G-CSF was given for a median duration of 6 days
(range 4-19 days). And the median total dose of G-CSF was
600 jig per body (range 300-1790 jg per body). There was no
correlation between total dose of G-CSF and interstitial pneu-
monia. One patient received concurrent G-CSF and bleomycin
chemotherapy. The G-CSF preparation used was filgrastim in
eight patients and lenograstim in twelve. Patients did not receive
any other medication, apart from anti-cancer agents, which might
have induced interstitial pneumonia.
Clinical characteristics at the onset of interstitial
pneumonia (Tables 4, 5 and 6)
Symptoms
The most common symptom of interstitial pneumonia was
dyspnoea (11 patients, 55%) followed by fever (ten patients, 50%).
Leucocyte andneutrophil counts andserum levels ofLDH
and CRP
At the onset of interstitial pneumonia the leucocyte count was
2 10 000 il-l in tenpatients andtheneutrophil countwas . 5000jl-'
in 11 patients. Interstitial pneumonia most frequently developed
6 days after the leucocyte (neutrophil) nadir or after rapid recovery
ofthe leucocyte count. At the onset ofinterstitial pneumonia, lactate
dehydrogenase (LDH) increased in 12 patients and C-reactive
protein (CRP) increased in 14 patients.
Imaging findings
The most common finding on chest radiograph films was a gran-
ular or reticular pattern throughout the lung fields, which was
observed in 12 patients, followed by a similarpattern involving the
lower fields ofboth lungs. CT scans ofthe chest showed a granular
or reticular pattern extending throughout both lungs in 77.8% of
patients.
Findings on bronchoalveolar lavage (BAL) and
transbronchial lung biopsy (TBLB)
BAL was performed in seven patients and the total cell count ofall
patients excluding one patient was measured. It was unmeasurable
in one patient. The total cell count increased in all six patients. The
percentage of lymphocytes and neutrophils increased in four and
two patients respectively. The CD4/CD8 ratio decreased in five
patients and it was less than 1. TBLB performed in three patients
shows typical histological changes of interstitial pneumonia.
Figure IA and B shows the changes in the same patient and Figure
IC shows the changes in another patient. These figure of typical
histological changes are similar to interstitial pneumonia, with the
apparent thickening of alveolar walls and infiltration of small
round cells. Also, a small amount ofintra-alveolarexudative pneu-
monia was observed, as well as granuloma formation in two cases.
Treatment and outcome
Ofthe 20 patients, 19 received steroid pulse therapy; the remaining
patientreceived 02 administration. A total of 17 patients who were
treated in the earliest part of the study period recovered, but three
patients in this group eventually died because ofrespiratory insuf-
ficiency and multiple organ failure.
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Table 4 Clinical symptoms at onset of interstitial pneumonia during treatment
with recombinant human granulocyte colony-stimulating factor
Clinical symptoms Number of patients (%)
Dyspnoea 11(55)
Fever (> 380C) 10 (50)
Shortness of breath 2 (10)
Cough 2 (10)
General fatigue 2 (10)
Dull headache 1 (5)
Table 5 Chest radiograph, chest CT and bronchoalveolar lavage findings at
onset of interstitial pneumonia during treatment with recombinant human
granulocyte colony-stimulating factor
Chest radiograph examination
Number of examined patients 19
Region of diffuse granular and reticular shadow
Bilateral whole lung fields 12 (63.2%)
Bilateral lower lung fields 5 (26.3%)
Right middle and lower lung field 1 (5.3%)
Right lower lung field 1 (5.3%)
Chest-CT examination
Number of examined patients 9
Region of diffuse granular and reticular shadow
Bilateral lung fields 7 (77.8%)
Right lung field 2 (22.2%)
Table 6 Bronchoalveolar lavage
Case Total number of cells Macrophage Neutrophil Lymphocyte Eosinophil CD4/CD8
(x 106 cells ml-1) (%) (%) (%) (%) ratio
1 14.0 19.0 52.0 21.0 8.0 1.71
2 2.5 30.8 6.9 62.3 0.0 0.41
3 14.3 27.4 56.8 15.3 0.0 0.8
4 10.2 32.4 9.0 58.6 0.0 0.5
5 14.0 17.0 8.0 74.0 1.0 0.53
6 13.9 18.0 4.0 74.0 2.0 0.89
7 ND* ND ND ND ND 1.16
*ND, not done.
DISCUSSION
G-CSF has been used to treat various forms of neutropenia. This
drug is believed to increase the neutrophil count and enhance
neutrophil function (Pettengell et al, 1992). The activation of
neutrophils is called a priming effect by which G-CSF enhances
neutrophil phagocytosis and migration as well as superoxide
production (Laver and Moore, 1989). These are important biolog-
ical defence mechanisms that primarily act to prevent bacterial
invasion but simultaneously enhance inflammatory reactions that
can injure host tissues (Weiland et al, 1986). It has been reported
that neutrophils are involved in the progression ofARDS. In BAL
fluid from patients with ARDS, neutrophils are increased in
number and there is an increase in neutrophil elastase activity
(Idell et al, 1985). In BAL fluid from patients with interstitial
pneumonia, the G-CSF production by alveolar macrophages is
increased significantly, suggesting involvement of G-CSF in the
pathogenesis ofthis condition (Tazi et al, 1991).
Interstitial pneumonia related to the use ofG-CSF has occasion-
ally been reported and many mechanisms have been proposed for
its aetiology. Matthews (1993) suggested that G-CSF might
augment the pneumotropic toxicity of BLM because pneumotoxi-
city occurred in three out of five patients with NHL who received
ABVD (doxorubicin, bleomycin, vinblastine and dacarbazin) plus
G-CSF. Dirix et al (1994) considered that BLM pneumonia might
be made worse by a rapid increase in the number and activity of
neutrophils because of G-CSF. BLM is thought to react with
Fe2+ to produce superoxide (02-), which damages DNA molecules
and gives rise to pulmonary dysfunction (Sausville et al, 1978).
According to Bastion et al (1994), who conducted two randomized
placebo-controlled trials in NHL patients to assess the effectiveness
ofG-CSF, chemotherapy including BLM given in combination with
G-CSF did not augment the pneumotropic toxicity of bleomycin.
Another clinical study assessed pulmonary disease in patients with
aggressive NHL who received BACOP (bleomycin, doxorubicin,
cyclophosphamide, vincristine, prednisolone) therapy with or
without G-CSF. Pneumonia occurred in 33% of patients receiving
BACOP with G-CSF and in 4% ofthe control patients. The authors
recommended that G-CSF shouldbe usedcarefully whencombined
with chemotherapy regimens that involve repeated BLM adminis-
tration over a long period (Lei et al, 1994). The mechanism by
which G-CSF when combined with certain anti-cancer agents gives
rise to pneumonia remains to be clarified. G-CSF has not been
reported to cause pneumonia in patients receiving it alone and it
only causespneumonia inpatients receiving combined therapy with
anti-cancer agents. This suggests that G-CSF increases the number
of activated neutrophils that exert a deleterious effects on sub-
clinical lung damage produced by anti-cancer agents and results in
the manifestation ofpulmonary dysfunction.
In addition to the effect on haemopoiesis, G-CSF enhances
mature neutrophil functions both in vitro and in vivo. Previous
studies indicated that G-CSF administration enhances superoxide
release in neutrophils from patients with maligant lymphoma
(Ohsaka et al, 1989). And Ohsaka et al (1993) reported that G-CSF
inversely regulates the surface expression of cellular adhesion
molecules on human neutrophils, that is G-CSF down-regulates
the expression of L-selectin and up-regulates the expression of
CDllb/CD18 leucocyte integrin on neutrophils. These findings
suggest that G-CSF may enhance host defence and participate in
the inflammatory process through the neutrophil-endothelial cell
interactions. However, neutrophil-derived oxygen metabolites and
proteinases have also been implicated in the pathogenesis oftissue
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Figure 1 (A) (B) Thickening of alveolar walls with small round cells
infiltration, granuloma formation and small amount of exudate are seen
(haematoxylin-eosin staining, HE x 100, elastica-Masson staining x 100).
(C) Thickening of alveolar walls with slight degree of small round cells
infiltration, swelling alveolar epithelium cells, granuloma-like histiocytic
agglutination and small amount of exudate are seen (HE x 67)
injury. Although the aetiology of interstitial pneumonia after
G-CSF application remains to be elucidated, activated or primed
neutrophils may participate in the development ofthe disease.
The present study showed that interstitial pneumonia secondary
to G-CSF has the following characteristics: (a) itoccurred predom-
inantly in older patients (>60 years); (b) it was prevalent among
patients with haematological malignancies, particularly NHL; (c)
all patients received G-CSF after administration of BLM, MTX,
CPA, VP-16 or other pneumotoxic anti-cancer agents; (d) the onset
ofinterstitial pneumonia occurred during administration of G-CSF
in 12 out of 20 patients; (e) the earliest symptoms of interstitial
pneumonia were usually dyspnoea and a temperature 2 38°C; (f)
the onset was associated with an increase in the leucocyte
(neutrophil) count in many cases; (g) initial elevation of the LDH
and CRPlevels was observed in 12 and 14patients respectively; (h)
on chest radiograph films, changes appeared first in the lower lung
fields and spread gradually over the entire lungs; (i) in many
patients, the total cell count in BAL fluid was increased; and (j)
alleviation of interstitial pneumonia was achieved in patients
treated by steroid pulse therapy soon after onset. In brief, when
G-CSF is given to patients who have previously received pneumo-
toxic anti-cancer agents, such as bleomycin and methotrexate,
pulmonary function should be monitored by measuring PaO2 and
% DLCO before and during G-CSF therapy.
Interstitial pneumonia should be suspected if dyspnoea and
fever are associated with rapidly increasing leucocyte and
neutrophil counts, as well as an elevation ofLDH and CRP during
administration of G-CSF. The diagnosis should be confirmed by
pulmonary function tests and chest radiograph examination. It is
important to start steroid pulse therapy as early as possible when
the diagnosis is made.
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